BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ghobrial RM, Farmer DG, Baquerizo A, Colquhoun S, Rosen HR, Yersiz H, Markmann JF, Drazan KE, Holt C, Imagawa D. Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg. 1999;229:824-831; discussion 831-833. [PMID: 10363896 DOI: 10.1097/00000658-199906000-00009] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Willems M, Metselaar H, Tilanus H, Schalm S, Man R. Liver transplantation and hepatitis C. Transplant Int 2002;15:61-72. [DOI: 10.1111/j.1432-2277.2002.tb00132.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
2 Crivellin C, De Martin E, Germani G, Gambato M, Senzolo M, Russo FP, Vitale A, Zanus G, Cillo U, Burra P. Risk factors in liver retransplantation: a single-center experience. Transplant Proc. 2011;43:1110-1113. [PMID: 21620065 DOI: 10.1016/j.transproceed.2011.01.141] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
3 Bahra M, Neumann UP, Jacob D, Berg T, Neuhaus R, Langrehr JM, Neuhaus P. Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C. Transpl Int. 2007;20:771-778. [PMID: 17617179 DOI: 10.1111/j.1432-2277.2007.00517.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
4 Fan ST, Cheung ST, Lo CM. Indications for liver transplantation in patients with chronic hepatitis B and C virus infection and hepatocellular carcinoma. J Gastroenterol Hepatol 2000;15 Suppl:E181-6. [PMID: 10921405 DOI: 10.1046/j.1440-1746.2000.02119.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
5 Moser MA. Options for Induction Immunosuppression in Liver Transplant Recipients: . Drugs 2002;62:995-1011. [DOI: 10.2165/00003495-200262070-00002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
6 Neumann UP, Berg T, Bahra M, Puhl G, Guckelberger O, Langrehr JM, Neuhaus P. Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up. Transplantation. 2004;77:226-231. [PMID: 14742986 DOI: 10.1097/01.tp.0000101738.27552.9d] [Cited by in Crossref: 218] [Cited by in F6Publishing: 39] [Article Influence: 12.1] [Reference Citation Analysis]
7 Zimmerman MA, Ghobrial RM. When shouldn't we retransplant? Liver Transpl 2005;:S14-20. [PMID: 16237729 DOI: 10.1002/lt.20599] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
8 Yoo HY, Maheshwari A, Thuluvath PJ. Retransplantation of liver: primary graft nonfunction and hepatitis C virus are associated with worse outcome. Liver Transpl. 2003;9:897-904. [PMID: 12942450 DOI: 10.1053/jlts.2003.50176] [Cited by in Crossref: 75] [Cited by in F6Publishing: 51] [Article Influence: 4.2] [Reference Citation Analysis]
9 Gurusamy KS, Tsochatzis E, Davidson BR, Burroughs AK. Antiviral prophylactic intervention for chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev. 2010;CD006573. [PMID: 21154370 DOI: 10.1002/14651858.cd006573.pub2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
10 Perumpail RB, Hahambis TA, Aggarwal A, Younossi ZM, Ahmed A. Treatment strategies for chronic hepatitis C prior to and following liver transplantation. World J Hepatol 2016; 8(1): 69-73 [PMID: 26783422 DOI: 10.4254/wjh.v8.i1.69] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
11 Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev. 2010;CD006803. [PMID: 20091608 DOI: 10.1002/14651858.CD006803.pub3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
12 Fasola CG, Klintmalm GB. Impact of immunosuppression in hepatitis C recurrence after liver transplantation: a controllable factor?: . Current Opinion in Organ Transplantation 2003;8:146-52. [DOI: 10.1097/00075200-200306000-00003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
13 Malkan G, Humar A, Lilly L, Greig PD, Grant D, Wanless IW, Cameron R, Levy GA, Cattrall MS. Natural history of recurrent hepatitis C after liver transplantation. Transplant Proc 2001;33:1468. [PMID: 11267376 DOI: 10.1016/s0041-1345(00)02554-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
14 Langrehr JM, Puhl G, Bahra M, Schmeding M, Spinelli A, Berg T, Schönemann C, Krenn V, Neuhaus P, Neumann UP. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation. Liver Transpl. 2006;12:644-651. [PMID: 16555324 DOI: 10.1002/lt.20648] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.6] [Reference Citation Analysis]
15 Lang H, Sotiropoulos GC, Beckebaum S, Fouzas I, Molmenti EP, Omar OS, Sgourakis G, Radtke A, Nadalin S, Saner FH, Malagó M, Gerken G, Paul A, Broelsch CE. Incidence of liver retransplantation and its effect on patient survival. Transplant Proc 2008;40:3201-3. [PMID: 19010234 DOI: 10.1016/j.transproceed.2008.09.039] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
16 Ghobrial RM, Gornbein J, Steadman R, Danino N, Markmann JF, Holt C, Anselmo D, Amersi F, Chen P, Farmer DG, Han S, Derazo F, Saab S, Goldstein LI, McDiarmid SV, Busuttil RW. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg. 2002;236:315-322; discussion 322-323. [PMID: 12192318 DOI: 10.1097/00000658-200209000-00008] [Cited by in Crossref: 130] [Cited by in F6Publishing: 118] [Article Influence: 6.5] [Reference Citation Analysis]
17 Russo MW, Galanko JA, Zacks SL, Beavers KL, Fried MW, Shrestha R. Impact of donor age and year of transplant on graft survival in liver transplant recipients with chronic hepatitis C. Am J Transplant. 2004;4:1133-1138. [PMID: 15196072 DOI: 10.1111/j.1600-6143.2004.00470.x] [Cited by in Crossref: 39] [Cited by in F6Publishing: 36] [Article Influence: 2.3] [Reference Citation Analysis]
18 Ghobrial RM, Yersiz H, Amersi F, Busuttil RW. Results of in situ splitting. In: Rogiers X, Bismuth H, Busuttil RW, Broering DC, Azoulay D, editors. Split liver transplantation. Heidelberg: Steinkopff; 2002. pp. 136-46. [DOI: 10.1007/978-3-642-57523-5_16] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
19 Burroughs AK. Posttransplantation prevention and treatment of recurrent hepatitis C. Liver Transpl 2000;6:s35-40. [DOI: 10.1053/jlts.2000.18690] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 0.9] [Reference Citation Analysis]
20 Powers JJ, Shumaker DA, Rosen HR. Liver transplantation for chronic hepatitis C: long-term results, role of antiviral therapy, and outcome of retransplantation: . Current Opinion in Organ Transplantation 2001;6:114-9. [DOI: 10.1097/00075200-200106000-00003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
21 Ghobrial RM, Shimoda M, Farmer DG, Yersiz H, Chen P, Dawson S, Amersi F, Han S, Goldstein LI, Martin P. Factors determining outcome of liver transplantation for hepatocellular carcinoma associated with hepatitis C cirrhosis. Transplant Proc. 2001;33:1358. [PMID: 11267326 DOI: 10.1016/S0041-1345(00)02509-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
22 Ghobrial RM. Retransplantation for recurrent hepatitis C. Liver Transpl. 2002;8:S38-S43. [PMID: 12362296 DOI: 10.1053/jlts.2002.35861] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 2.4] [Reference Citation Analysis]
23 Shimoda M, Saab S, Morrisey M, Ghobrial RM, Farmer DG, Chen P, Han SH, Bedford RA, Goldstein LI, Martin P. A cost-effectiveness analysis of biliary anastomosis with or without T-tube after orthotopic liver transplantation. Am J Transplant. 2001;1:157-161. [PMID: 12099364 DOI: 10.1034/j.1600-6143.2001.10210.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
24 McCaughan GW, Zekry A. Effects of immunosuppression and organ transplantation on the natural history and immunopathogenesis of hepatitis C virus infection. Transpl Infect Dis. 2000;2:166-185. [PMID: 11429029 DOI: 10.1034/j.1399-3062.2000.020403.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.2] [Reference Citation Analysis]
25 Biggins S. Should HCV-related cirrhosis be a contraindication for retransplantation? Liver Transplantation 2003;9:236-8. [DOI: 10.1053/jlts.2003.50048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
26 Garcia JH, Araújo Filho AH, Braga LL, Viana CF, Rocha TD, Pereira KB. PEGYLATED INTERFERON AND RIBAVIRIN FOR TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION: a single-liver transplant center experience in Brazil. Arq Gastroenterol 2015;52:216-21. [PMID: 26486290 DOI: 10.1590/S0004-28032015000300012] [Reference Citation Analysis]
27 Villamil F, Levy G, Grazi GL, Mies S, Samuel D, Sanjuan F, Rossi M, Lake J, Munn S, Mühlbacher F. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine. Transplant Proc. 2006;38:2964-2967. [PMID: 17112875 DOI: 10.1016/j.transproceed.2006.08.131] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.7] [Reference Citation Analysis]
28 Sung RS, Pomfret EA, Andreoni KA, Baker TB, Peters TG. The high-risk recipient: the Eighth Annual American Society of Transplant Surgeons' State-of-the-Art Winter Symposium. Clin Transplant 2010;24:23-8. [PMID: 19919609 DOI: 10.1111/j.1399-0012.2009.01156.x] [Reference Citation Analysis]
29 Sheiner PA. Immunosuppressive modifications in hepatitis C: . Current Opinion in Organ Transplantation 2001;6:327-30. [DOI: 10.1097/00075200-200112000-00010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.0] [Reference Citation Analysis]
30 Jain AB, Eghtesad B, Venkataramanan R, Fontes PA, Kashyap R, Dvorchik I, Shakil AO, Kingery L, Fung JJ. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl. 2002;8:1007-1013. [PMID: 12424713 DOI: 10.1053/jlts.2002.36241] [Cited by in Crossref: 45] [Cited by in F6Publishing: 39] [Article Influence: 2.4] [Reference Citation Analysis]
31 Shiffman ML, Vargas HE, Everson GT. Controversies in the management of hepatitis C virus infection after liver transplantation. Liver Transpl. 2003;9:1129-1144. [PMID: 14586872 DOI: 10.1053/jlts.2003.50261] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
32 Hemming AW, Cattral MS, Reed AI, Van Der Werf WJ, Greig PD, Howard RJ. Liver transplantation for hepatocellular carcinoma. Ann Surg. 2001;233:652-659. [PMID: 11323504 DOI: 10.1097/00000658-200105000-00009] [Cited by in Crossref: 241] [Cited by in F6Publishing: 219] [Article Influence: 11.5] [Reference Citation Analysis]
33 Teixeira R, Papatheodoridis GV, Burroughs AK. Management of recurrent hepatitis C after liver transplantation. J Viral Hepat 2001;8:159-68. [DOI: 10.1046/j.1365-2893.2001.00282.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 0.9] [Reference Citation Analysis]
34 Germani G, Tsochatzis E, Papastergiou V, Burroughs AK. HCV in liver transplantation. Semin Immunopathol. 2013;35:101-110. [PMID: 22829333 DOI: 10.1007/s00281-012-0329-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
35 Abdelmalek MF, Firpi RJ, Soldevila-Pico C, Reed AI, Hemming AW, Liu C, Crawford JM, Davis GL, Nelson DR. Sustained viral response to interferon and ribavirin in liver transplant recipients with recurrent hepatitis C. Liver Transpl. 2004;10:199-207. [PMID: 14762857 DOI: 10.1002/lt.20074] [Cited by in Crossref: 124] [Cited by in F6Publishing: 112] [Article Influence: 6.9] [Reference Citation Analysis]
36 Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl. 2007;13:21-29. [PMID: 17192906 DOI: 10.1002/lt.21035] [Cited by in Crossref: 126] [Cited by in F6Publishing: 102] [Article Influence: 8.4] [Reference Citation Analysis]
37 Biggins SW, Terrault NA. Management of Recurrent Hepatitis C in Liver Transplant Recipients. Infectious Disease Clinics of North America 2006;20:155-74. [DOI: 10.1016/j.idc.2006.01.011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
38 Taltavull T. Impact of cyclosporine on the development of immunosuppressive therapy in liver transplantation. Transplantation Proceedings 2004;36:S291-4. [DOI: 10.1016/j.transproceed.2003.12.032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
39 Samuel D, Kimmoun E. Immunosuppression in hepatitis B virus and hepatitis C virus transplants: special considerations. Clin Liver Dis 2003;7:667-81. [PMID: 14509533 DOI: 10.1016/s1089-3261(03)00057-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
40 Ghobrial RM, Yersiz H, Farmer DG, Amersi F, Goss J, Chen P, Dawson S, Lerner S, Nissen N, Imagawa D. Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg. 2000;232:312-323. [PMID: 10973381 DOI: 10.1097/00000658-200009000-00003] [Cited by in Crossref: 99] [Cited by in F6Publishing: 88] [Article Influence: 4.5] [Reference Citation Analysis]
41 Cisneros L, Londoño MC, Blasco C, Bataller R, Miquel R, Bruguera M, Ginès P, Rimola A. Hepatic stellate cell activation in liver transplant patients with hepatitis C recurrence and in non-transplanted patients with chronic hepatitis C. Liver Transpl 2007;13:1017-27. [PMID: 17600343 DOI: 10.1002/lt.21178] [Cited by in F6Publishing: 18] [Reference Citation Analysis]
42 Saab S, Hu R, Ibrahim AB, Goldstein LI, Kunder G, Durazo F, Han S, Yersiz H, Ghobrial RM, Farmer DG. Discordance between ALT values and fibrosis in liver transplant recipients treated with ribavirin for recurrent hepatitis C. Am J Transplant. 2003;3:328-333. [PMID: 12614290 DOI: 10.1034/j.1600-6143.2003.00053.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
43 Bahr MJ, Beckermann JG, Rifai K, Gehrmann L, Rosenau J, Klempnauer J, Strassburg CP, Manns MP. Retrospective analysis of the impact of immunosuppression on the course of recurrent hepatitis C after liver transplantation. Transplant Proc. 2005;37:1703-1704. [PMID: 15919437 DOI: 10.1016/j.transproceed.2005.02.103] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
44 Angelis M, Cooper JT, Freeman RB. Impact of donor infections on outcome of orthotopic liver transplantation. Liver Transpl. 2003;9:451-462. [PMID: 12740786 DOI: 10.1053/jlts.2003.50094] [Cited by in Crossref: 71] [Cited by in F6Publishing: 54] [Article Influence: 3.7] [Reference Citation Analysis]
45 Watt KD, Burak K, Deschênes M, Lilly L, Marleau D, Marotta P, Mason A, Peltekian KM, Renner EL, Yoshida EM; Canadian Transplant Hepatology Outcomes Research Network. Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol 2006;20:725-34. [PMID: 17111055 DOI: 10.1155/2006/238218] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
46 Singh G, Selby R, Genyk Y, Mateo R, Sher L, Jabbour N. Using hepatitis-positive donors for solid organ transplantation: . Current Opinion in Organ Transplantation 2003;8:341-7. [DOI: 10.1097/00075200-200312000-00014] [Reference Citation Analysis]
47 Leonardi M, Boin I, Leonardi L. Late hepatic artery thrombosis after liver transplantation: clinical setting and risk factors. Transplantation Proceedings 2004;36:967-9. [DOI: 10.1016/j.transproceed.2004.03.121] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
48 Yao FY, Saab S, Bass NM, Hirose R, Ly D, Terrault N, Lazar AA, Bacchetti P, Ascher NL, Roberts JP. Prediction of survival after liver retransplantation for late graft failure based on preoperative prognostic scores. Hepatology. 2004;39:230-238. [PMID: 14752842 DOI: 10.1002/hep.20005] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 4.5] [Reference Citation Analysis]
49 Ben-ari Z, Mor E, Bar-nathan N, Shaharabani E, Shapira Z, Tur-kaspa R. Comparison of tacrolimus with cyclosporin as primary immunosuppression in patients with hepatitis C virus infection after liver transplantation. Transplantation Proceedings 2003;35:612-3. [DOI: 10.1016/s0041-1345(03)00009-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
50 Tamura S, Sugawara Y. Treatment strategy for hepatitis C after liver transplantation. J Hepatobiliary Pancreat Surg 2008;15:111-23. [DOI: 10.1007/s00534-007-1295-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
51 Gurusamy KS, Tsochatzis E, Toon CD, Davidson BR, Burroughs AK. Antiviral prophylaxis for the prevention of chronic hepatitis C virus in patients undergoing liver transplantation. Cochrane Database Syst Rev 2013;:CD006573. [PMID: 24297303 DOI: 10.1002/14651858.CD006573.pub3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
52 Davis GL. The challenge of progressive hepatitis C following liver transplantation. Liver Transpl 2006;12:19-21. [PMID: 16382454 DOI: 10.1002/lt.20576] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
53 Hügle T, Cerny A. Current therapy and new molecular approaches to antiviral treatment and prevention of hepatitis C. Rev Med Virol 2003;13:361-71. [PMID: 14625884 DOI: 10.1002/rmv.397] [Cited by in Crossref: 51] [Cited by in F6Publishing: 44] [Article Influence: 2.8] [Reference Citation Analysis]
54 Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci. 2002;47:450-455. [PMID: 11855567 DOI: 10.1023/a: 1013759230800] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
55 Onaca NN, Levy MF, Sanchez EQ, Chinnakotla S, Fasola CG, Thomas MJ, Weinstein JS, Murray NG, Goldstein RM, Klintmalm GB. A correlation between the pretransplantation MELD score and mortality in the first two years after liver transplantation. Liver Transpl. 2003;9:117-123. [PMID: 12548503 DOI: 10.1053/jlts.2003.50027] [Cited by in Crossref: 160] [Cited by in F6Publishing: 142] [Article Influence: 8.4] [Reference Citation Analysis]
56 Gow PJ, Angus PW. Disease recurrence after liver transplantation: Need we worry? Journal of Gastroenterology and Hepatology 2002;17:733-6. [DOI: 10.1046/j.1440-1746.2002.02741.x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
57 Ahmed A, Keeffe EB. Hepatitis C virus and liver transplantation. Clin Liver Dis. 2001;5:1073-1090. [PMID: 11685796 DOI: 10.1016/s1089-3261(05)70210-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
58 Futagawa Y, Terasaki PI, Waki K, Cai J, Gjertson DW. No improvement in long-term liver transplant graft survival in the last decade: an analysis of the UNOS data. Am J Transplant. 2006;6:1398-1406. [PMID: 16686763 DOI: 10.1111/j.1600-6143.2006.01256.x] [Cited by in Crossref: 64] [Cited by in F6Publishing: 55] [Article Influence: 4.0] [Reference Citation Analysis]
59 Barshes NR, Udell IW, Lee TC, O'mahony CA, Karpen SJ, Carter BA, Goss JA. The natural history of hepatitis C virus in pediatric liver transplant recipients. Liver Transpl 2006;12:1119-23. [DOI: 10.1002/lt.20793] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 2.6] [Reference Citation Analysis]
60 Chan K, Yeh J, Sun W. The role of autonomic dysfunction in predicting 1-year mortality after liver transplantation. Liver Int 2017;37:1239-48. [DOI: 10.1111/liv.13364] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
61 Rodriguez-luna H, Vargas HE. Management of hepatitis C virus infection in the setting of liver transplantation. Liver Transpl 2005;11:479-89. [DOI: 10.1002/lt.20424] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 2.2] [Reference Citation Analysis]
62 Berenguer M, López-Labrador FX, Wright TL. Hepatitis C and liver transplantation. J Hepatol. 2001;35:666-678. [PMID: 11690716 DOI: 10.1016/s0168-8278(01)00179-9] [Cited by in Crossref: 222] [Cited by in F6Publishing: 45] [Article Influence: 11.1] [Reference Citation Analysis]
63 Northup PG, Pruett TL, Kashmer DM, Argo CK, Berg CL, Schmitt TM. Donor Factors Predicting Recipient Survival After Liver Retransplantation: The Retransplant Donor Risk Index. Am J Transplant 2007;7:1984-8. [DOI: 10.1111/j.1600-6143.2007.01887.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
64 Wiesner RH, Rakela J, Ishitani MB, Mulligan DC, Spivey JR, Steers JL, Krom RA. Recent advances in liver transplantation. Mayo Clin Proc. 2003;78:197-210. [PMID: 12583530 DOI: 10.4065/78.2.197] [Cited by in Crossref: 69] [Cited by in F6Publishing: 48] [Article Influence: 3.6] [Reference Citation Analysis]
65 Khalili M, Vardanian AJ, Hamerski CM, Wang R, Bacchetti P, Roberts JP, Terrault NA. Management of hepatitis C-infected liver transplant recipients at large North American centres: changes in recent years. Clin Transplant 2006;20:1-9. [DOI: 10.1111/j.1399-0012.2005.00449.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
66 Jothimani D, Govil S, Rela M. Management of post liver transplantation recurrent hepatitis C infection with directly acting antiviral drugs: a review. Hepatol Int 2016;10:749-61. [PMID: 27337961 DOI: 10.1007/s12072-016-9744-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.7] [Reference Citation Analysis]
67 Jain A, Miller D, Schreibman I, Riley TR 3rd, Krok KL, Dohi T, Sharma R, Kadry Z. Is there increased risk of hepatocellular carcinoma recurrence in liver transplant patients with direct-acting antiviral therapy? Hepatol Int 2019;13:190-8. [PMID: 30680672 DOI: 10.1007/s12072-019-09930-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
68 Wall WJ, Khakhar A. Retransplantation for recurrent hepatitis C: The argument against. Liver Transplantation;9:S73-8. [DOI: 10.1053/jlts.2003.50258] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.7] [Reference Citation Analysis]
69 Alonso O, Loinaz C, Abradelo M, Pérez B, Manrique A, Gómez R, Jiménez C, Meneu JC, García I, Moreno-González E. Changes in the incidence and severity of recurrent hepatitis C after liver transplantation over 1990-1999. Transplant Proc 2003;35:1836-7. [PMID: 12962815 DOI: 10.1016/s0041-1345(03)00604-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
70 Onaca N, Levy MF, Ueno T, Martin AP, Sanchez EQ, Chinnakotla S, Randall HB, Dawson Iii S, Goldstein RM, Davis GL, Klintmalm GB. An outcome comparison between primary liver transplantation and retransplantation based on the pretransplant MELD score. Transplant Int 2006;19:282-7. [DOI: 10.1111/j.1432-2277.2006.00281.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
71 Charlton M. Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep 2007;9:23-30. [DOI: 10.1007/s11894-008-0017-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
72 de Arias AE, Haworth SE, Belli LS, Burra P, Pinzello G, Vangeli M, Minola E, Guido M, Boccagni P, De Feo TM. Killer cell immunoglobulin-like receptor genotype and killer cell immunoglobulin-like receptor-human leukocyte antigen C ligand compatibility affect the severity of hepatitis C virus recurrence after liver transplantation. Liver Transpl. 2009;15:390-399. [PMID: 19326408 DOI: 10.1002/lt.21673] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
73 Jiao M, Greanya ED, Haque M, Yoshida EM, Soos JG. Methadone maintenance therapy in liver transplantation. Prog Transplant 2010;20:209-14; quiz 215. [PMID: 20929104 DOI: 10.7182/prtr.20.3.r8n4k17212158k62] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
74 Yu C, Gifford AL, Christiansen CL, Drainoni ML. Hepatitis C Is Poorly Associated With Drug Use in Cambodian Americans in Lowell, Massachusetts. Open Forum Infect Dis 2016;3:ofw099. [PMID: 27419171 DOI: 10.1093/ofid/ofw099] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
75 Saab S, Wang V. Recurrent hepatitis C following liver transplant: diagnosis, natural history, and therapeutic options. J Clin Gastroenterol 2003;37:155-63. [PMID: 12869888 DOI: 10.1097/00004836-200308000-00013] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
76 Samuel, Feray. Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat 2000;7:87-92. [DOI: 10.1046/j.1365-2893.2000.00202.x] [Cited by in Crossref: 42] [Cited by in F6Publishing: 34] [Article Influence: 1.9] [Reference Citation Analysis]
77 Rayhill SC, Kirby PA, Voigt MD, La Brecque DR, Lutz CT, Katz DA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Heisey D, Wu YM, Schmidt WN. Positive Serum Cryoglobulin Is Associated with Worse Outcome after Liver Transplantation for Chronic Hepatitis C: . Transplantation 2005;80:448-56. [DOI: 10.1097/01.tp.0000164826.84041.f0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
78 Biggins SW, Terrault NA. Treatment of recurrent hepatitis C after liver transplantation. Clin Liver Dis. 2005;9:505-523, ix. [PMID: 16023980 DOI: 10.1016/j.cld.2005.05.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
79 Ghobrial RM, Gornbein J, Steadman R, Danino N, Markmann JF, Holt C, Anselmo D, Amersi F, Chen P, Farmer DG. Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg. 2002;236:315-322; discussion 322-323. [PMID: 12192318 DOI: 10.1097/01.sla.0000026684.68004.1e] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
80 Roche B, Samuel D. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat. 2007;14 Suppl 1:89-96. [PMID: 17958649 DOI: 10.1111/j.1365-2893.2007.00920.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 70] [Article Influence: 5.4] [Reference Citation Analysis]
81 . Screening of donor and recipient prior to solid organ transplantation. Am J Transplant 2004;4 Suppl 10:10-20. [PMID: 15504205 DOI: 10.1111/j.1600-6135.2004.00616.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
82 Jain A, Sharma R, Ryan C, Safadjou S, Kashyap R, Mantry P, Maliakkal B, Orloff M. Response to antiviral therapy in liver transplant recipients with recurrent hepatitis C viral infection: a single center experience. Clinical Transplantation 2010;24:104-11. [DOI: 10.1111/j.1399-0012.2009.00961.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
83 Bahr M, Manns M. Recurrent hepatitis C in transplanted patients: more questions than answers. Digestive and Liver Disease 2003;35:2-6. [DOI: 10.1016/s1590-8658(02)00003-8] [Cited by in Crossref: 5] [Article Influence: 0.3] [Reference Citation Analysis]
84 Jiao M, Greanya ED, Haque M, Yoshida EM, Soos JG. Methadone Maintenance Therapy in Liver Transplantation. Prog Transpl 2010;20:209-14. [DOI: 10.1177/152692481002000303] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
85 Saab S. Is it cost-effective to treat recurrent hepatitis C infection in orthotopic liver transplantation patients? Liver Transplantation 2002;8:449-57. [DOI: 10.1053/jlts.2002.32717] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.3] [Reference Citation Analysis]
86 Gurusamy KS, Osmani B, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2009;:CD006803. [PMID: 19160303 DOI: 10.1002/14651858.CD006803.pub2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
87 Ercolani G, Grazi GL, Ravaioli M, Del Gaudio M, Cescon M, Varotti G, Ramacciato G, Vetrone G, Zanello M, Pinna AD. Histological recurrent hepatitis C after liver transplantation: Outcome and role of retransplantation. Liver Transpl 2006;12:1104-11. [DOI: 10.1002/lt.20725] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
88 Sun N, Zhang J, Li X, Zhang C, Zhou X. Biliary tract reconstruction with or without T-tube in orthotopic liver transplantation: a systematic review and meta-analysis. Expert Rev Gastroenterol Hepatol. 2015;9:529-538. [PMID: 25583036 DOI: 10.1586/17474124.2015.1002084] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
89 Gurusamy KS, Tsochatzis E, Toon CD, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral interventions for liver transplant patients with recurrent graft infection due to hepatitis C virus. Cochrane Database Syst Rev. 2013;12:CD006803. [PMID: 24307460 DOI: 10.1002/14651858.cd006803.pub4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.1] [Reference Citation Analysis]
90 Teixeira R, Pastacaldi S, Papatheodoridis GV, Burroughs AK. Recurrent hepatitis C after liver transplantation. J Med Virol 2000;61:443-54. [DOI: 10.1002/1096-9071(200008)61:4<443::aid-jmv6>3.0.co;2-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
91 Sotiropoulos GC, Sgourakis G, Radtke A, Molmenti EP, Goumas K, Mylona S, Fouzas I, Karaliotas C, Lang H. Orthotopic liver transplantation: T-tube or not T-tube? Transplantation. 2009;87:1672-1680. [PMID: 19502959 DOI: 10.1097/tp.0b013e3181a5cf3f] [Cited by in Crossref: 56] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
92 Paik SW, Tan HP, Klein AS, Boitnott JK, Thuluvath PJ. Outcome of orthotopic liver transplantation in patients with hepatitis C. Dig Dis Sci 2002;47:450-5. [PMID: 11855567 DOI: 10.1023/a:1013759230800] [Cited by in Crossref: 13] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
93 Briceño J, Ciria R, Pleguezuelo M, Naranjo A, Sánchez-Hidalgo J, Ruiz-Rabelo J, López-Cillero P, Luque A, de la Mata M, Rufián S. Contribution of marginal donors to liver transplantation for hepatitis C virus infection. Transplant Proc 2007;39:2297-9. [PMID: 17889169 DOI: 10.1016/j.transproceed.2007.07.069] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.7] [Reference Citation Analysis]
94 Bekker J, Ploem S, de Jong KP. Early hepatic artery thrombosis after liver transplantation: a systematic review of the incidence, outcome and risk factors. Am J Transplant. 2009;9:746-757. [PMID: 19298450 DOI: 10.1111/j.1600-6143.2008.02541.x] [Cited by in Crossref: 327] [Cited by in F6Publishing: 239] [Article Influence: 25.2] [Reference Citation Analysis]
95 Jiménez-Romero C, Justo I, Marcacuzco A, García V, Manrique A, García-Sesma Á, Calvo J, Fernández I, Martín-Arriscado C, Caso Ó. Safe use of livers from deceased donors older than 70 years in recipients with HCV cirrhosis treated with direct-action antivirals. Retrospective cohort study. Int J Surg 2021;91:105981. [PMID: 34098075 DOI: 10.1016/j.ijsu.2021.105981] [Reference Citation Analysis]
96 Shimoda M, Ghobrial RM, Carmody IC, Anselmo DM, Farmer DG, Yersiz H, Chen P, Dawson S, Durazo F, Han S. Predictors of survival after liver transplantation for hepatocellular carcinoma associated with Hepatitis C. Liver Transpl. 2004;10:1478-1486. [PMID: 15558585 DOI: 10.1002/lt.20303] [Cited by in Crossref: 78] [Cited by in F6Publishing: 64] [Article Influence: 4.6] [Reference Citation Analysis]
97 Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, Radke C, Neuhaus P. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepatol. 2004;41:830-836. [PMID: 15519657 DOI: 10.1016/j.jhep.2004.06.029] [Cited by in Crossref: 281] [Cited by in F6Publishing: 246] [Article Influence: 16.5] [Reference Citation Analysis]
98 Pandey P, Pandey A, Dillhoff M, Schmidt C, Kamel IR, Pawlik TM. Assessing the Non-tumorous Liver: Implications for Patient Management and Surgical Therapy. J Gastrointest Surg 2018;22:344-60. [PMID: 28924922 DOI: 10.1007/s11605-017-3562-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
99 Azarbal B, Poommipanit P, Arbit B, Hage A, Patel J, Kittleson M, Kar S, Kaldas FM, Busuttil RW. Feasibility and safety of percutaneous coronary intervention in patients with end-stage liver disease referred for liver transplantation. Liver Transpl. 2011;17:809-813. [PMID: 21425429 DOI: 10.1002/lt.22301] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
100 Sheil A. Liver transplantation for hepatitis and hepatoma. Transplantation Proceedings 2002;34:2463-4. [DOI: 10.1016/s0041-1345(02)03177-9] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
101 Lerner SM, Markmann J, Jurim O, Busuttil RW. Retransplantation. Transplantation of the Liver. Elsevier; 2005. pp. 767-75. [DOI: 10.1016/b978-0-7216-0118-2.50056-2] [Cited by in Crossref: 3] [Article Influence: 0.2] [Reference Citation Analysis]
102 de Vera ME, Smallwood GA, Rosado K, Davis L, Martinez E, Sharma S, Stieber AC, Heffron TG. INTERFERON-?? AND RIBAVIRIN FOR THE TREATMENT OF RECURRENT HEPATITIS C AFTER LIVER TRANSPLANTATION1: . Transplantation 2001;71:678-86. [DOI: 10.1097/00007890-200103150-00019] [Cited by in Crossref: 84] [Cited by in F6Publishing: 72] [Article Influence: 4.0] [Reference Citation Analysis]
103 Wairimu F, Ward NC, Liu Y, Dwivedi G. Cardiac Transplantation in HIV-Positive Patients: A Narrative Review. J Acquir Immune Defic Syndr 2021;87:763-8. [PMID: 33534274 DOI: 10.1097/QAI.0000000000002647] [Reference Citation Analysis]
104 Abouljoud MS, Escobar F, Douzdjian V, Bajjoka I, Moonka D, Shick L, Brown KA. Recurrent disease after liver transplantation. Transplant Proc 2001;33:2716-9. [PMID: 11498137 DOI: 10.1016/s0041-1345(01)02159-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
105 Oh CK, Pelletier SJ, Sawyer RG, Dacus AR, McCullough CS, Pruett TL, Sanfey HA. Uni- and multi-variate analysis of risk factors for early and late hepatic artery thrombosis after liver transplantation. Transplantation. 2001;71:767-772. [PMID: 11330540 DOI: 10.1097/00007890-200103270-00014] [Cited by in Crossref: 147] [Cited by in F6Publishing: 116] [Article Influence: 7.0] [Reference Citation Analysis]
106 Briceño J, Ruiz J, Ciria R, Naranjo A, Sánchez-hidalgo J, Luque A, Rufián S, de la Mata M, López-cillero P. Factors Affecting Survival and Tumor Recurrence in Patients Transplanted for Hepatocellular Carcinoma and Coexistent Hepatitis C Virus. Transplantation Proceedings 2008;40:2990-3. [DOI: 10.1016/j.transproceed.2008.09.022] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
107 Ghobrial RM, Steadman R, Gornbein J, Lassman C, Holt CD, Chen P, Farmer DG, Yersiz H, Danino N, Collisson E, Baquarizo A, Han SS, Saab S, Goldstein LI, Donovan JA, Esrason K, Busuttil RW. A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients. Ann Surg 2001;234:384-93; discussion 393-4. [PMID: 11524591 DOI: 10.1097/00000658-200109000-00012] [Cited by in Crossref: 197] [Cited by in F6Publishing: 179] [Article Influence: 9.4] [Reference Citation Analysis]
108 Brown KA, Moonka DK. Liver transplantation. Curr Opin Gastroenterol 2000;16:290-4. [PMID: 17023888 DOI: 10.1097/00001574-200005000-00013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
109 Yoo PS, Umman V, Rodriguez-Davalos MI, Emre SH. Retransplantation of the liver: review of current literature for decision making and technical considerations. Transplant Proc. 2013;45:854-859. [PMID: 23622570 DOI: 10.1016/j.transproceed.2013.02.063] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
110 Punzalan CS, Barry C, Zacharias I, Rodrigues J, Mehta S, Bozorgzadeh A, Barnard GF. Sofosbuvir plus simeprevir treatment of recurrent genotype 1 hepatitis C after liver transplant. Clin Transplant. 2015;29:1105-1111. [PMID: 26358816 DOI: 10.1111/ctr.12634] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
111 Forman LM. To transplant or not to transplant recurrent hepatitis C and liver failure. Clinics in Liver Disease 2003;7:615-29. [DOI: 10.1016/s1089-3261(03)00053-9] [Cited by in Crossref: 23] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
112 Pelletier SJ, Schaubel DE, Punch JD, Wolfe RA, Port FK, Merion RM. Hepatitis C is a risk factor for death after liver retransplantation. Liver Transpl. 2005;11:434-440. [PMID: 15776460 DOI: 10.1002/lt.20342] [Cited by in Crossref: 67] [Cited by in F6Publishing: 49] [Article Influence: 3.9] [Reference Citation Analysis]
113 Jain A. Microemulsion cyclosporine with C2 monitoring and tacrolimus in liver transplantation with or without hepatitis C virus infection. Liver Transpl 2006;12:1452-4. [PMID: 17004248 DOI: 10.1002/lt.20818] [Reference Citation Analysis]
114 Schmidt SC, Bahra M, Bayraktar S, Berg T, Schmeding M, Pratschke J, Neuhaus P, Neumann U. Antiviral treatment of patients with recurrent hepatitis C after liver transplantation with pegylated interferon. Dig Dis Sci. 2010;55:2063-2069. [PMID: 19798575 DOI: 10.1007/s10620-009-0982-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
115 Saxena R, Crawford JM, Navarro VJ, Friedman AL, Robert ME. Utilization of acidophil bodies in the diagnosis of recurrent hepatitis C infection after orthotopic liver transplantation. Mod Pathol 2002;15:897-903. [PMID: 12218206 DOI: 10.1038/modpathol.3880626] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
116 Ramos-casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14:64-72. [DOI: 10.1177/096120330501400114] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
117 Ramos-casals M, Font J. Mycophenolate mofetil in patients with hepatitis C virus infection. Lupus 2005;14:64-72. [DOI: 10.1191/0961203305lu2122oa] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
118 Waghray A, O'Shea R, Pai R, Menon KV. Hepatocellular carcinoma complicating recurrent hepatitis C after liver transplantation. Hepatology 2013;58:1854-5. [PMID: 23744815 DOI: 10.1002/hep.26548] [Reference Citation Analysis]
119 Rayhill SC, Wu YM, Katz DA, Voigt MD, Labrecque DR, Kirby PA, Mitros FA, Kalil RS, Miller RA, Stolpen AH, Schmidt WN. Older donor livers show early severe histological activity, fibrosis, and graft failure after liver transplantation for hepatitis C. Transplantation. 2007;84:331-339. [PMID: 17700157 DOI: 10.1097/01.tp.0000270313.31328.63] [Cited by in Crossref: 73] [Cited by in F6Publishing: 67] [Article Influence: 4.9] [Reference Citation Analysis]
120 Gane E. The natural history and outcome of liver transplantation in hepatitis C virus-infected recipients. Liver Transpl. 2003;9:S28-S34. [PMID: 14586892 DOI: 10.1053/jlts.2003.50248] [Cited by in Crossref: 170] [Cited by in F6Publishing: 153] [Article Influence: 9.4] [Reference Citation Analysis]
121 Al-Freah MAB, Moran C, Foxton MR, Agarwal K, Wendon JA, Heaton ND, Heneghan MA. Impact of comorbidity on waiting list and post-transplant outcomes in patients undergoing liver retransplantation. World J Hepatol 2017; 9(20): 884-895 [PMID: 28804571 DOI: 10.4254/wjh.v9.i20.884] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
122 Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003;9:1053-1061. [PMID: 14526400 DOI: 10.1053/jlts.2003.50208] [Cited by in Crossref: 54] [Cited by in F6Publishing: 43] [Article Influence: 3.0] [Reference Citation Analysis]
123 Kallwitz ER, Cotler SJ. Care of the Liver Transplant Patient. Disease-a-Month 2008;54:486-507. [DOI: 10.1016/j.disamonth.2008.03.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
124 Levy G, Grazi GL, Sanjuan F, Wu Y, Mühlbacher F, Samuel D, Friman S, Jones R, Cantisani G, Villamil F. 12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine microemulsion (C2 monitoring) and tacrolimus. Liver Transpl. 2006;12:1464-1472. [PMID: 17004259 DOI: 10.1002/lt.20802] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
125 Onaca NN, Levy MF, Netto GJ, Thomas MJ, Sanchez EQ, Chinnakotla S, Fasola CG, Weinstein JS, Murray N, Goldstein RM, Klintmalm GB. Pretransplant MELD Score As a Predictor of Outcome After Liver Transplantation for Chronic Hepatitis C: Worse Outcome With Higher MELD Scores. American Journal of Transplantation 2003;3:626-30. [DOI: 10.1034/j.1600-6143.2003.00092.x] [Cited by in Crossref: 57] [Cited by in F6Publishing: 58] [Article Influence: 3.0] [Reference Citation Analysis]
126 Han SH, Ofman J, Holt C, King K, Kunder G, Chen P, Dawson S, Goldstein L, Yersiz H, Farmer DG. An efficacy and cost-effectiveness analysis of combination hepatitis B immune globulin and lamivudine to prevent recurrent hepatitis B after orthotopic liver transplantation compared with hepatitis B immune globulin monotherapy. Liver Transpl. 2000;6:741-748. [PMID: 11084061 DOI: 10.1053/jlts.2000.18702] [Cited by in Crossref: 178] [Cited by in F6Publishing: 154] [Article Influence: 8.1] [Reference Citation Analysis]
127 Sumitran-holgersson S, Joshi M, Olausson M. Fetal Liver Cell Transplantation. In: Bhattacharya N, Stubblefield P, editors. Human Fetal Tissue Transplantation. London: Springer; 2013. pp. 219-35. [DOI: 10.1007/978-1-4471-4171-6_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
128 Dai WC, Chan SC, Chok KS, Cheung TT, Sharr WW, Chan AC, Fung JY, Wong TC, Lo CM. Retransplantation using living-donor right-liver grafts. J Hepatobiliary Pancreat Sci 2014;21:579-84. [PMID: 24550160 DOI: 10.1002/jhbp.100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
129 Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, Sánchez-Hidalgo J, Marchal T, Rufián S, López-Cillero P. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009;15:37-48. [PMID: 19109846 DOI: 10.1002/lt.21566] [Cited by in Crossref: 69] [Cited by in F6Publishing: 56] [Article Influence: 5.3] [Reference Citation Analysis]
130 Sponseller CA, Ramrakhiani S. Treatment of hepatitis B and C following liver transplantation. Curr Gastroenterol Rep 2002;4:52-62. [DOI: 10.1007/s11894-002-0038-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
131 Everson G. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transplantation 2002;8:S19-27. [DOI: 10.1053/jlts.2002.35852] [Cited by in Crossref: 105] [Cited by in F6Publishing: 97] [Article Influence: 5.3] [Reference Citation Analysis]
132 Qasim A, Zaman BM, Geoghegan J, Maguire D, Traynor O, Hegarty J, McCormick PA. Significant influence of the primary liver disease on the outcomes of hepatic retransplantation. Ir J Med Sci 2009;178:47-51. [PMID: 18982406 DOI: 10.1007/s11845-008-0234-z] [Reference Citation Analysis]
133 Watt KD, Lyden ER, McCashland TM. Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl. 2003;9:1019-1024. [PMID: 14526394 DOI: 10.1053/jlts.2003.50206] [Cited by in Crossref: 82] [Cited by in F6Publishing: 67] [Article Influence: 4.6] [Reference Citation Analysis]
134 Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology. 2002;122:889-896. [PMID: 11910340 DOI: 10.1053/gast.2002.32418] [Cited by in Crossref: 871] [Cited by in F6Publishing: 766] [Article Influence: 43.6] [Reference Citation Analysis]
135 Izzy M, Jibara G, Aljanabi A, Alani M, Giannattasio E, Zaidi H, Said Z, Gaglio P, Wolkoff A, Reinus JF. Limited Fibrosis Progression but Significant Mortality in Patients Ineligible for Interferon-Based Hepatitis C Therapy. J Clin Exp Hepatol 2016;6:100-8. [PMID: 27493457 DOI: 10.1016/j.jceh.2016.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
136 Nemes B, Sárváry E, Gerlei Z, Fazakas J, Doros A, Németh A, Görög D, Fehérvári I, Máthé Z, Gálffy Z, Pár A, Schuller J, Telegdy L, Fehér J, Lotz G, Schaff Z, Nagy P, Járay J, Lengyel G. The recurrence of hepatitis C virus after liver transplantation. Orvosi Hetilap 2007;148:1971-9. [DOI: 10.1556/oh.2007.28176] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
137 Charlton M. Patient and graft survival following liver transplantation for hepatitis C: Much ado about something. Gastroenterology 2002;122:1162-5. [DOI: 10.1053/gast.2002.32745] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
138 Nakamura T, Shirouzu T. Antibody-Mediated Rejection and Recurrent Primary Disease: Two Main Obstacles in Abdominal Kidney, Liver, and Pancreas Transplants. J Clin Med 2021;10:5417. [PMID: 34830699 DOI: 10.3390/jcm10225417] [Reference Citation Analysis]